Search CommunityWalk:


BioMarker Strategies

855 N.Wolfe St., Suite 603
Baltimore, MD, USA

Category: Diagnostic/Imaging

Used in the following map:

Maryland Biotech Industry Map

BioMarker Strategies is a tissue-based cancer diagnostics company that is focused on the development of the SnapPath(TM) ex vivo biomarker platform to improve the treatment of cancer. The company was founded in 2006 by Scott Allocco and Douglas P. Clark.

BioMarker's SnapPath(TM) biomarker testing system is an automated live tumor cell processing platform that enables next-generation predictive tests known as Functional Signaling Profiles (FSPs) to guide targeted drug therapy selection for individual cancer patients. Its SnapPath (TM) platform uniquely enables the ex vivo induction of functional biomarkers to show the response of patient's live tumor cells to pathway stimulants (such as growth factors) and inhibitors (targeted drugs).

BioMarker has an agreement with the National Cancer Institute (NCI).